Dipal Divecha, PA
Physician Assistant · Sugarland, TXNPI 1023351384
Payments from drug & device makers
Across 417 payments — averaging $37.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$8K
- Amgen$1K
- Novo Nordisk$951
- Lilly USA, LLC$564
- Corcept Therapeutics$402
- Ascendis Pharma Endocrinology Inc$397
- plus $4K from 33 others
What the payments were for
- Speaking & faculty fees$7,40348%
- Food & beverage$8,12252%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 27 | $7,837 |
| Amgen | 44 | $1,130 |
| Novo Nordisk | 47 | $951 |
| Lilly USA, LLC | 35 | $564 |
| Corcept Therapeutics | 18 | $402 |
| Ascendis Pharma Endocrinology Inc | 11 | $397 |
| Radius Health, Inc. | 20 | $365 |
| AstraZeneca(2 entities) | 18 | $337 |
| AbbVie | 22 | $309 |
| Tandem Diabetes Care, Inc. | 12 | $299 |
| Dexcom, Inc. | 23 | $277 |
| BETA Bionics, Inc. | 11 | $270 |
| Xeris Pharmaceuticals, Inc. | 13 | $231 |
| Boehringer Ingelheim | 12 | $225 |
| Bayer | 14 | $216 |
| Abbott | 12 | $205 |
| IBSA Pharma Inc. | 11 | $183 |
| Sanofi-aventis U.S. LLC | 10 | $175 |
| Mannkind Corporation | 9 | $155 |
| Cequr Corporation | 2 | $145 |
| Antares Pharma, Inc. | 7 | $118 |
| Madrigal Pharmaceuticals | 4 | $84 |
| Amneal Pharmaceuticals LLC | 5 | $81 |
| Medtronic | 3 | $74 |
| Alvogen Inc | 3 | $68 |
| Avvisto Therapeutics, LLC | 3 | $68 |
| Zealand Pharma US, Inc. | 4 | $64 |
| Ascensia Diabetes Care US Inc. | 3 | $55 |
| Tolmar, Inc. | 3 | $51 |
| Neurocrine Biosciences, Inc. | 1 | $30 |
| Pfizer | 2 | $27 |
| Amphastar Pharmaceuticals, Inc. | 1 | $22 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,537 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 127 | $164,097 |
| OzempicSemaglutide | 84 | $112,071 |
| FarxigaDapagliflozin Propanediol | 26 | $22,068 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $21,032 |
| Xigduo XrDapaglifloz Propaned/Metformin | 20 | $20,764 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 24 | $20,627 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $18,544 |
| SynthroidLevothyroxine Sodium | 21 | $2,590 |
| Levothyroxine Sodium | 43 | $360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $564 | $164,097127 claims |
| Novo NordiskOzempic | $951 | $112,07184 claims |
| AstraZenecaFarxiga | $337 | $22,06826 claims |
| Boehringer IngelheimSynjardy Xr | $225 | $20,62724 claims |
| AbbVieSynthroid | $309 | $2,59021 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $81 | $36043 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Sugarland
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.